Blood Science Update: The Dual Role of BCL11B in T-Cell Malignancies

Blood Science Update: The Dual Role of BCL11B in T-Cell Malignancies

Blood Science continues to lead the way in elucidating  complex biological processes and their implications in disease. In this insightful review article, “Dual role of BCL11B in T-cell malignancies,” Grzegorz K. Przybylski, Julia Przybylska, and Yangqiu Li explore the paradoxical functions of the B-cell CLL/lymphoma 11B (BCL11B) gene in T-cell development and malignancies.

KEYMAKER-U03 Study: Advancing Immunotherapy in ccRCC

The KEYMAKER-U03 Substudy 03B evaluated pembrolizumab-based immunotherapy combinations in advanced clear cell renal cell carcinoma (ccRCC) after progression on PD-(L)1 and VEGF-TKI therapies.Results show that pembrolizumab + quavonlimab (anti-CTLA-4) and…
Blood Science Update: Versatility of Megakaryocytes in Health and Disease

Blood Science Update: Versatility of Megakaryocytes in Health and Disease

This article, published in the esteemed journal Blood Science, explores the remarkable adaptability of megakaryocytes (MKs) in various physiological and pathological processes. Renowned for its pioneering work in hematology, Blood Science has showcased groundbreaking insights into the dynamic roles of MKs beyond their traditional function in platelet production, offering a deeper understanding of their involvement in immune modulation, aging, and hematological diseases.
Throwback to SABCS 2024: Dr. Matteo Lambertini on Risk-Reducing Surgery in Young BRCA Carriers

Throwback to SABCS 2024: Dr. Matteo Lambertini on Risk-Reducing Surgery in Young BRCA Carriers

At SABCS 2024, Dr. Matteo Lambertini shared insights from a major international study examining the role of risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) in young BRCA carriers with breast cancer. The study, which analyzed data from 5,290 patients across 109 centers worldwide, offers a deeper understanding of how these surgeries impact long-term survival.
Throwback to SABCS 2024: Dr. Icro Meattini on the EUROPA Trial – Optimizing Treatment for Older Women with Early Breast Cancer

Throwback to SABCS 2024: Dr. Icro Meattini on the EUROPA Trial – Optimizing Treatment for Older Women with Early Breast Cancer

At SABCS 2024, Dr. Icro Meattini presented a preplanned interim analysis of the EUROPA trial, a randomized phase III study comparing exclusive endocrine therapy (ET) vs. radiation therapy (RT) in women aged 70+ with luminal-like early breast cancer. The study aimed to evaluate quality of life (HRQOL) and ipsilateral breast tumor recurrence (IBTR) to guide treatment decisions in this patient population.
Throwback to SABCS 2024: Dr. Mafalda Oliveira on HER3-DXd in High-Risk HR+/HER2- Early Breast Cancer

Throwback to SABCS 2024: Dr. Mafalda Oliveira on HER3-DXd in High-Risk HR+/HER2- Early Breast Cancer

Throwback to SABCS 2024, where Dr. Mafalda Oliveira presented findings from the SOLTI VALENTINE phase II trial, evaluating HER3-DXd alone or in combination with letrozole as a neoadjuvant treatment for high-risk HR+/HER2-negative early breast cancer (EBC). The study explored whether HER3-DXd could serve as an effective and tolerable alternative to standard multi-agent chemotherapy.